Add time:08/15/2019         Source:sciencedirect.com

Intracerebroventricular (i.c.v.) administration of [D-Trp11]neurotensin to rats decreased locomotor activity at a low dose (30 ng) and increased it at a high dose (750 ng). Only this high dose increased the dopamine turnover in the nucleus accumbens. The locomotor stimulant effect elicited by this high dose was potentiated by the dopamine uptake inhibitor, GBR 12783 (1-[2-(di- phenyl-methoxy)ethyl]4-(3-phenyl-2-propenyl) piperazine) (5 mg/kg, i.p.), and reduced by the dopamine releaser, dexam- (1.5 mg/kg). It was suppressed by the bilateral injection of 6-hydroxydopamine (8 μg/2 μl) into the nucleus accumbens when rats were tested 4 days after the lesion. Fifteen days after lesion, the i.c.v. administration of 750 ng of [D-Trp11]neurotensin induced hypolocomotion during the first hour of the test, and hyperlocomotion during the second hour. This latter locomotor stimulant effect was suppressed by the dopamine antagonist, haloperidol (50 μg/kg, i.p.). Thus, the hypokinetic effect of 30 ng [D-Trp11]neurotensin is independent of dopamine transmission, whereas the hyperkinesia elicited by 750 ng proceeds via an increased in dopamine transmission in the nucleus accumbens.

We also recommend Trading Suppliers and Manufacturers of [D- TRP11 ]-NEUROTENSIN (cas 100929-52-0). Pls Click Website Link as below: cas 100929-52-0 suppliers